Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Diabetes gene linked to Alzheimer’s

Researchers from Mount Sinai School of Medicine have identified a gene that causes diabetes kills nerve cells in the brain, possibly resulting in Alzheimer’s disease.

20 Jul 2011

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Bristol-Myers Squibb Company and AstraZeneca today reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.

20 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

First Edition: July 19, 2011

Kaiser Health News staff writer Christopher Weaver reports: "New consumer-controlled health insurance plans could get seed money from the government to increase competition - and maybe cut prices -- under new rules announced Monday by the Department of Health and Human Services".

19 Jul 2011

BioMarin commences BMN 673 Phase 1 trial in hematological malignancies

BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.

15 Jul 2011

UW scientists determine atomic architecture of sodium channel

Scientists at the University of Washington (UW) in Seattle have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for molecular medicine researchers around the world in designing better drugs for pain, epilepsy, and heart rhythm disturbances.

14 Jul 2011

Researchers capitalize on 'memories' of adult-derived stem cells for treatment of diabetes

Stem cells from early embryos can be coaxed into becoming a diverse array of specialized cells to revive and repair different areas of the body. Therapies based on these stem cells have long been contemplated for the treatment of diabetes, but have been held back by medical and ethical drawbacks.

14 Jul 2011

Roundup: N.H.'s Planned Parenthood funding dilemma; Calif. prison doc's high pay, little work

The highest-paid state employee in California last year, a prison surgeon who took home $777,423, has a history of mental illness, was fired once for alleged incompetence and has not been allowed to treat an inmate for six years because medical supervisors don't trust his clinical skills. Since July 2005, Dr. Jeffrey Rohlfing has mostly been locked out of his job — on paid leave or fired or fighting his termination — at High Desert State Prison in Susanville, state records show.

14 Jul 2011

Gerresheimer second quarter revenues increase 5.9% to EUR 284.5m

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, has closed successfully the second quarter of the 2011 financial year

13 Jul 2011

Study may help explain why antipsychotic drugs can promote overeating, weight gain

Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, may explain why some antipsychotic drugs can promote overeating, weight gain, and insulin resistance.

12 Jul 2011

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Generex Biotechnology Corporation today announced preliminary clinical results of two major trials using the Generex Oral-lyn formulation that will be used for registration and marketing.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

Exenatide tQT clinical trial meets pre-specified primary endpoint

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

8 Jul 2011

Solution for treating obesity-related diseases may reside in fat tissue

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality – not just the quantity – of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals. The study, which is a special feature on the iPAD version of the Journal of the American College of Cardiology, provides compelling evidence that the answer to treating cardiovascular disease and other obesity-related disorders, such as type 2 diabetes and cancer, might be found in the adipose tissue itself.

7 Jul 2011

Gene therapy may help prevent progression of type 1 diabetes

Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.

7 Jul 2011

New biological insights into fat tissue

For better or worse, a popular class of anti-diabetic drugs does more than lower blood sugar. One known as rosiglitazone has been in the spotlight for its possible link to increased cardiovascular events, but it also seems to come with unexplained vascular benefits and an unwelcome tendency for weight gain.

6 Jul 2011

Adipose tissue might serve as target for treating obesity-related disorders

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality - not just the quantity - of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals.

5 Jul 2011

Intravenous nutrition does not have a positive effect if administered early

Critically ill patients receive intravenous nutrition - via an infusion in a large vein - when nutrition via a stomach or intestinal tube is insufficient. There is international dispute over the correct timing of intravenous nutrition: European guidelines recommend administering intravenous nutrition within 48 hours to prevent malnutrition.

1 Jul 2011

Amylin behaves when guarded by zinc

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving.

1 Jul 2011

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

As strange as it sounds, a new research study published in the FASEB Journal (http://www.fasebj.org), suggests that the "healthy" ingredient in red wine, resveratrol, may prevent the negative effects that spaceflight and sedentary lifestyles have on people.

1 Jul 2011